Recent events
Recent events tied to this brand in public sources.
Back to profile26 entries · Page 2 of 2
2019
Cipla acquires Vysov brand and trademark rights
Cipla acquired the brand name and trademark rights for Vysov and Vysov M, brands for the antidiabetic drug Vildagliptin, for the Indian market.
2019
Cipla acquires Vysov trademark rights
Cipla acquired the brand name and trademark rights for Vysov and Vysov M, its anti-diabetic drug brands, for the Indian market.
2019
Cipla announces acquisition of Elores from Venus Remedies
Cipla announced the acquisition of the anti-infective product Elores from Venus Remedies for the Indian market.
2019
Cipla acquires Elores for the Indian market
Cipla said it had acquired the anti-infective product Elores from Venus Remedies for the Indian market. The deal value was not disclosed.
2019
Cipla launches Daptomycin Injection in the US
Cipla said it launched Daptomycin Injection, a generic version of Cubicin used to treat complicated skin infections, in the US market.
2019
USFDA classifies inspection of Cipla's Goa facility as OAI
The USFDA classified its inspection of Cipla's Goa manufacturing facility, conducted from 16 to 27 September 2019, as Official Action Indicated (OAI). Cipla said it did not believe this would have a material impact on its US business at that stage and would work with the agency to address the observations.